Aripiprazole CAS 129722-12-9 Purity >99.0% (HPLC) API
AbaPhakathi boBonelelo boMvelisi be-Aripiprazole Ngobunyulu obuPhezulu
Aripiprazole API CAS 129722-12-9
1-(2,3-Dichlorophenyl)piperazine Hydrochloride CAS 119532-26-2
I-7-Hydroxy-3,4-Dihydro-2 (1H)-Quinolinone CAS 22246-18-0
7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone CAS 129722-34-5
| Igama leMchiza | Aripiprazole |
| Izithethantonye | 7-[4-[4-(2,3-Dichlorophenyl)-1-Piperazinyl]butoxy]-3,4-Dihydro-2(1H)-Quinolinone |
| Inombolo yeCAS | 129722-12-9 |
| Inombolo yeCAT | RF-PI2270 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
| Ifomula yeemolekyuli | I-C23H27Cl2N3O2 |
| Ubunzima beMolekyuli | 448.39 |
| Ukunyibilika | Ukunyibilika okunganyibilikiyo emanzini;Ayinyibiliki kwiMethanol |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Umgubo weCrystalline oMhlophe okanye ophantse wamhlophe |
| Ukuchongwa | Nge-IR;Nge-HPLC |
| Ukunyibilika | Inyibilika kwiAcetic Acid, Inyibilika kancinane kwiEthanol |
| Indawo yokunyibilika | 136.0 ~ 140.0℃ |
| Ilahleko ekomisweni | <0.50% |
| Intsalela kwi-Ignition | <0.10% |
| Iintsimbi ezinzima | ≤20ppm |
| Izinyibilikisi ezishiyekileyo | |
| I-Ethanol | ≤1000ppm |
| I-DMF | ≤200ppm |
| Izinto ezinxulumeneyo | |
| Nakuphi na Ukungacoceki Okukodwa | <0.20% |
| Ukungcola ngokupheleleyo | <1.00% |
| Ubunyulu / Indlela yokuHlalutya | >99.0% (HPLC) |
| Isivavanyi | 98.0% ~ 102.0% (kwiSiseko esingenamanzi) |
| Imida emincinci | |
| Ubalo olupheleleyo lweAerobic Microbial | ≤1000 cfu/g |
| Igwele kunye noMngundo zidibene | ≤100 cfu/g |
| E·Coli | Ukungabikho |
| ULungiselelo lwePathogenic | Ukungabikho |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | API;I-Antipsychotic |
Iphakheji: Ibhotile, 5kg/aluminiyam inkonkxa, 25kg/Cardboard Drum, okanye ngokwemfuno umthengi
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma
I-Aripiprazole (CAS: 129722-12-9) luhlobo olutsha lwezinto eziphuma kwi-quinoline ezine-lipid ezinyibilikayo, uphawu lweziphumo ze-pharmacological kukuba ayisiyiyo kuphela i-postsynaptic dopamine D2 receptor antagonist, kodwa kunye ne-presynaptic dopamine D2 receptor agonist, ingakwazi kwakhona. vuyisa i-D1, i-D3, i-D4 receptors.I-Aripiprazole sisizukulwana sesibini se-atypical antipsychotic kunye ne-anti-depressant kunye nomsebenzi we-agonist oyingxenye kwi-dopamine D2 kunye ne-serotonin i-5-HT1A receptors kunye nomsebenzi ochasayo kwi-serotonin 5-HT2A receptors.Amaxabiso e-Ki yi-0.34 nM, 0.8 nM, 1.7 nM, kunye ne-3.4 nM, ngokulandelanayo, kwi-dopamine D2 kunye ne-D3, i-serotonin 5-HT1A kunye ne-5-HT2A receptors.I-Aripiprazole isetyenziselwa unyango lwe-schizophrenia kunye nokuphazamiseka kwengqondo okuhlobene.I-Bristol-Myers Squibb kunye ne-Otsuka Pharmaceutical Company yazisa ukuba i-European Union ivume i-Abilify (i-Aripiprazole) kunyango lwesicelo soluhlu lwe-schizophrenia.I-schizophrenia ichaphazela i-1% yabemi behlabathi, kwaye ngakumbi kubantu abadala abancinci.I-schizophrenia ichaphazela ukucinga, ukulawula iimvakalelo kunye nokukwazi ukwenza izigqibo zesigulana.Izigulana ezine-schizophrenia-positive ziya kuba neempawu ezifana nemibono kunye nokukhohlisa, izigulane ezineempawu ezingathandekiyo zokuhoxiswa kwentlalo, ukungabikho kweenguqu zengqondo.Ngo-2002 i-FDA yavuma i-Abilify kunyango lwe-schizophrenia, olunamandla edosi amahlanu: 5 mg, 10 mg, 15 mg, 20 mg kunye ne-30 mg, ukususela ekuvunyweni kwayo.
